If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
The most common applications are as an ingredient in dietary supplement, in cosmetics, as flavoring for foods, such as turmeric-flavored beverages in South and Southeast Asia, and as coloring for foods, such as curry powders, mustards, butters, and cheeses. As a food additive for orange-yellow coloring in prepared foods, its E number is E 100 in the European Union. It is also approved by the U.S. FDA to be used as a food coloring in US.
== Research use == Since C. hemisphaerica passes through planula, polyp, and medusa stages during its life cycle, it is regarded as a good model for studying how one genome can produce variable phenotypes. This is especially useful when considering that two of the more common Cnidarian model organisms, Hydra and Nematostella, do not have the same "complete' life-cycle that alternates between a vegetative polyp and sexually reproducing, free-swimming medusa form. Clytia has characteristics that make it favorable for laboratory culture and experimental manipulation. All stages of Clytia's life cycle can be reproduced under laboratory conditions; polyp colonies, due to their essentially immortal nature, are easily maintained, and adult medusa can be fed with Artemia larvae. Adult male and female medusa spawn daily, and can be entrained with controlled light conditions to spawn at specific times. The oocytes, eggs, embryos, and planulae of Clytia are easily visualized under a microscope and, much like those of popular model organisms like sea urchins, the zygotes of C. hemisphaerica are relatively large (around 200 um in diameter) and can be microinjected to form transgenic planulae, polyp colonies, and medusa. Clytia is also unique in that its gonads can function autonomously; a gonad separated from an adult medusa will undergo oocyte development and ovulation under the same entrained light cues as would a gonad still attached to a medusa.
Solar distillation relies on sunlight to warm and evaporate the water to be purified which then condenses and trickles into a container. In theory, a solar (condensation) still removes all pathogens, salts, metals, and most chemicals but in field practice the lack of clean components, easy contact with dirt, improvised construction, and disturbances result in cleaner, yet contaminated water.
Sources: en.wikipedia.org
=== Bow–Bro === E. J. Bowen (1898–1980), English physical chemist known for research into fluorescence Humphry Bowen (1929–2001), English analytical chemist known for radioisotopes and trace elements Paul D. Boyer (1918–2018), American biochemist known for studying the biosynthesis of adenosine triphosphate (ATP), 1997 Nobel Prize in Chemistry Robert Boyle (1627–1691), Irish-English pioneer of modern chemistry, best known for Boyle's law Henri Braconnot (1780–1855), French chemist who worked on plant chemistry and discovered chitin and pectin Henning Brand (c. 1630–c.1692 or c. 1710), German alchemist, who accidentally discovered phosphorus while searching for the "philosopher's stone" Mary Bidwell Breed (1870–1949), American chemist focusing on aromatic acids and the atomic mass of palladium Ronald Breslow (1931–2017), American organic chemist who designed and synthesized new molecules with interesting properties, such as the cyclopropenyl cation Alan Brisdon (21st century), British chemist known for Inorganic Spectroscopic Methods Johannes Nicolaus Brønsted (1879–1947), Danish chemist known for work on reaction kinetics, especially acid–base reactions Herbert C.
Different cell types within adipose tissue exhibit distinct DNA methylation patterns. Mature adipocytes and adipose progenitor cells (ASPCs) show a high degree of hypomethylation, affecting more than 50% of their regulatory regions. This hypomethylation is associated with the activation of genes involved in triglyceride synthesis, such as glycerol‑3‑phosphate acyltransferase 1 (GPAM). In contrast, myeloid cells display approximately 73% hypermethylated regions, reflecting an epigenetic program opposite to that of the adipocytic lineage. Overall, there is a direct relationship between DNA demethylation and gene expression, whereby highly expressed genes tend to exhibit low methylation levels. These epigenetic patterns contribute to defining the functional identity of the different cell types within subcutaneous adipose tissue (SAT).
The addition of bicarbonate to the intravenous fluids may alleviate acidosis (high acid level of the blood) and make the urine more alkaline to prevent cast formation in the kidneys; evidence suggesting that bicarbonate has benefits above saline alone is limited, and it can worsen hypocalcemia by enhancing calcium and phosphate deposition in the tissues. If urine alkalinization is used, the pH of the urine is kept at 6.5 or above. Furosemide, a loop diuretic, is often used to ensure sufficient urine production, but evidence that this prevents kidney failure is lacking.
== Academic career == In 1974, Candace Pert earned a Ph.D. in pharmacology from Johns Hopkins University School of Medicine, where she worked in the laboratory of Solomon Snyder and discovered the brain's opiate receptor. Pert conducted a National Institutes of Health Postdoctoral Fellowship with the Department of Pharmacology at the Johns Hopkins University School of Medicine from 1974 to 1975. She conducted research at the National Institute of Mental Health from 1975 to 1987. In 1983, she became the Chief of the Section on Brain Biochemistry of the Clinical Neuroscience Branch, the only female chief at NIMH. She left to found and direct a private biotech laboratory in 1987. Pert was a research professor in the department of physiology and biophysics at Georgetown University School of Medicine in Washington, D.C. In her latter years, she was with RAPID Pharmaceuticals. In 1997 she published her book Molecules of Emotion. She appeared as one of the experts in Bill Moyers 1993 PBS video production, "Healing and the Mind", and in the 2004 film What the #$*! Do We Know!?. She died on September 12, 2013, in Potomac, Maryland.
Sources: en.wikipedia.org
== Interactions == Concomitant or recent (previous 14 days) monoamine oxidase inhibitor (MAOI) use can lead to hypertensive reactions, including hypertensive crisis, and should be avoided. Clinical studies have found minimal or no influence of certain MAOIs like the weak non-selective MAOI linezolid and the potent selective MAO-B inhibitor selegiline (as a transdermal patch) on the pharmacokinetics of pseudoephedrine. This is in accordance with the fact that pseudoephedrine is not metabolized by monoamine oxidase (MAO). However, pseudoephedrine induces the release of norepinephrine, which MAOIs inhibit the metabolism of, and as such, MAOIs can still potentiate the effects of pseudoephedrine. No significant pharmacodynamic interactions have been found with selegiline, but linezolid potentiated blood pressure increases with pseudoephedrine. However, this was deemed to be without clinical significance in the case of linezolid, though it was noted that some individuals may be more sensitive to the sympathomimetic effects of pseudoephedrine and related agents. Pseudoephedrine is contraindicated with MAOIs like phenelzine, tranylcypromine, isocarboxazid, and moclobemide due to the potential for synergistic sympathomimetic effects and hypertensive crisis. It is also considered to be contraindicated with linezolid and selegiline as some individuals may react more sensitively to coadministration.
In 2001, they published a retraction after researchers at other laboratories were unable to duplicate the results and the Berkeley lab could not duplicate them either. In June 2002, the director of the lab announced that the original claim of the discovery of these two elements had been based on data fabricated by principal author Victor Ninov. Newer experimental results and theoretical predictions have confirmed the exponential decrease in cross sections with lead and bismuth targets as the atomic number of the resulting nuclide increases.
The beef hormone controversy or beef hormone dispute is a disagreement over the use of growth hormones in beef production. In 1989, the European Communities banned the import of meat that contained artificial beef growth hormones, although they were approved for use in the United States. In 2003 estradiol-17β was permanently banned, while provisionally banning five others. World Trade Organization (WTO) rules permit such bans, but only where a signatory presents valid scientific evidence that the ban is a health and safety measure. Canada and the United States opposed this ban, taking the EU to the WTO Dispute Settlement Body. In 1997, the WTO Dispute Settlement Body ruled against the EU. It remains one of the most intractable agricultural trade controversies since the establishment of the WTO. It is not the same as the UK–EU dispute over bovine spongiform encephalopathy, although both have been termed the "beef war".
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.